Seres Therapeutics
MCRB
93 hedge funds and large institutions have $342M invested in Seres Therapeutics in 2020 Q2 according to their latest regulatory filings, with 23 funds opening new positions, 40 increasing their positions, 15 reducing their positions, and 6 closing their positions.
283% more first-time investments, than exits
New positions opened: 23 | Existing positions closed: 6
167% more repeat investments, than reductions
Existing positions increased: 40 | Existing positions reduced: 15
41% more capital invested
Capital invested by funds: $242M → $342M (+$100M)
21% more funds holding
Funds holding: 77 → 93 (+16)
2% more call options, than puts
Call options by funds: $3.53M | Put options by funds: $3.45M
0.19% more ownership
Funds ownership: 4.76% → 4.96% (+0.19%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$16.8M |
| 2 |
BlackRock
New York
|
+$2.57M |
| 3 |
Millennium Management
New York
|
+$1.62M |
| 4 |
D.E. Shaw & Co
New York
|
+$1.43M |
| 5 |
Renaissance Technologies
New York
|
+$1.39M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NAMA
Nikko Asset Management Americas
New York
|
-$4.47M |
| 2 |
Sumitomo Mitsui Trust Group
Minato-Ku, Tokyo,
Japan
|
-$4.47M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$1.79M |
| 4 |
JP Morgan Chase
New York
|
-$635K |
| 5 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$257K |
MCRB Hedge Fund Activity: Q2 2020 in Review
93 of the 4,888 institutional investors tracked by Wall St. Rank reported a position in Seres Therapeutics (MCRB) for Q2 2020, worth a combined $342M — up 41% from $242M a quarter earlier.
Buyers outnumbered sellers: 23 funds opened new MCRB positions and 6 closed out — a net gain of 17 holders — while 40 added to existing stakes and 15 trimmed.
The largest buyer was ARK Investment Management, adding an estimated $16.8M. The largest seller was Nikko Asset Management Americas, cutting an estimated $4.47M.
- 93 institutional investors held Seres Therapeutics (MCRB) as of Q2 2020, up from 77 in Q1 2020.
- Funds reported $342M of Seres Therapeutics stock for Q2 2020, up 41% quarter-over-quarter.
- 23 funds opened new Seres Therapeutics positions in Q2 2020 and 6 closed out, a net change of +17 holders.
- The largest Seres Therapeutics buyer in Q2 2020 was ARK Investment Management, an estimated $16.8M added.
- The largest Seres Therapeutics seller in Q2 2020 was Nikko Asset Management Americas, an estimated $4.47M sold.
Based on aggregated 13F filings for Q2 2020.